Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATX101 (Allay Therapeutics, 483d4f)
- Development stage
- Unknown
- Lead developer
- Allay Therapeutics
- Modality
- Small Molecules
- Administration
- Local
01
Overview
ATX101 is an investigational, non-opioid, ultra-sustained-release local anesthetic implant developed by Allay Therapeutics for the management of acute post-operative pain, specifically following total knee arthroplasty (TKA). The product consists of bupivacaine, a well-characterized sodium channel blocker, integrated into a proprietary biopolymer-based matrix. This dissolvable implant is designed to be placed at the surgical site during closure, where it provides continuous, localized pain relief for up to three weeks as the polymer gradually degrades into water and carbon dioxide. ATX101 is currently in Phase 2 clinical development in the United States and Phase 1/2 in Japan in collaboration with Maruishi Pharmaceutical.
- Other names
- Allay
02
Targets
PCNA (Proliferating cell nuclear antigen)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on ATX101 (Allay Therapeutics, 483d4f).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATX101 (Allay Therapeutics, 483d4f).